Lunch & Learn: Strategies for Protecting Biomarker Innovation in the US and Abroad

Recent decisions by the US Supreme Court have found both isolated DNA and methods of assessing drug treatment efficacy by measuring metabolite levels are not eligible for patent protection. From these decisions, it’s become clear that the hard work of identifying a gene, or set of genes, which are correlated with a disease state is not enough to receive patent protection in the US. In contrast, isolated DNA is eligible for patent protection in many jurisdictions outside the US, such as Europe.

Moving forward, companies will likely consider innovation protection strategies which include some mix of patent and trade secret protection.

• Insight regarding the impact of these decisions and strategies for protecting biomarker innovation in the US and abroad
• Understanding which biomarker innovations are patent-eligible in the US and abroad
• Information enabling companies to craft a global innovation and protection strategy

Speaker:

• Django Andrews

• Early registration is highly advised as space is limited and there will be no on-site registration
• Late arrivals will not be admitted after 11:30AM
• Pre-registered attendees will receive an immediate receipt/confirmation after submission
• Please print this receipt/confirmation and bring it with you to receive your conference credentials
• Photo ID (driver’s license or passport) will be required at check-in
• All sales are final

Please mail your event-related questions to: registration@baybio.org or you can contact us via phone: 650-871-3257.

Is your company a member? Click here to check.
See how your company can save money by becoming a BayBio member!